Revenue for Q1 FY23 has increased by 1.8% YoY to ₹40,727 millions. Profits decreased by 12% YoY to ₹5,183 millions because Total Expenditure grew by 7% YoY for Q1 FY 2023.
In this quarter’s results, it is clearly visible that the pharmacy business has been affected by the US price erosions. As per the management, the increase in input cost has also affected the bottom line.